An ongoing, randomized, three‐arm, phase 2/3 study is comparing gilteritinib plus azacitidine vs each agent alone in patients with newly diagnosed, FLT3‐mutated AML who were aged ≥75 years or ineligible for intensive therapy.59 This evidence concerns the gene FLT3 and acute myeloid leukemia.